C. Stevens
A5040324221- Lipoproteins and Cardiovascular Health
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Nutritional Studies and Diet
- Genetic factors in colorectal cancer
- Hormonal Regulation and Hypertension
- Cancer Risks and Factors
- Colorectal Cancer Screening and Detection
- Atherosclerosis and Cardiovascular Diseases
- Esophageal Cancer Research and Treatment
- Lipid metabolism and disorders
- Health Systems, Economic Evaluations, Quality of Life
- Antioxidant Activity and Oxidative Stress
- Water-Energy-Food Nexus Studies
- Machine Learning in Healthcare
- Artificial Intelligence in Healthcare
- Medication Adherence and Compliance
- Apelin-related biomedical research
- Health and Medical Research Impacts
- Artificial Intelligence in Healthcare and Education
- Metabolism, Diabetes, and Cancer
- Scottish History and National Identity
- Cardiovascular Disease and Adiposity
- Health Promotion and Cardiovascular Prevention
- Nutrition and Health in Aging
Imperial College London
2015-2025
European Atherosclerosis Society
2021
Deutsches Diabetes-Zentrum e.V.
2017
St Mary's Hospital
2017
Abstract Background and Aims Overweight obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence individuals with heterozygous familial hypercholesterolaemia (HeFH) whether they confer additional of ASCVD independent LDL cholesterol (LDL-C) remains unclear. Methods Cross-sectional analysis was conducted 35 540 patients HeFH across 50 countries, EAS FH Studies Collaboration registry. Prevalence World Health...
<h2>Summary</h2><h3>Background</h3> Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults were diagnosed before age 18 years via current diagnostic approaches, which derived from observations in adults. We aimed to characterise and adolescents heterozygous (HeFH) understand approaches the identification management inform future public health strategies. <h3>Methods</h3> For this cross-sectional study, we assessed younger...
Familial hypercholesterolemia (FH), while highly prevalent, is a significantly underdiagnosed monogenic disorder. Improved detection could reduce the large number of cardiovascular events attributable to poor case finding. We aimed assess whether machine learning algorithms outperform clinical diagnostic criteria (signs, history, and biomarkers) recommended screening in United Kingdom identifying individuals with FH-causing variants, presenting scalable for general populations.
Background: Elevated lipoprotein(a) [Lp(a)] is an inherited, currently non-modifiable risk marker that increases lifetime ASCVD risk. Guidance vary on Lp(a) levels at which increases; hence prevalence of “elevated” depends putative thresholds e.g. >1.3 billion people globally have Lp(a)≥125 nmol/L. are >90% genetically determined and stable throughout life; measurement once in adulthood recommended. Awareness may change patient management with more intensive control traditional...
This is an overview of the EAS Familial Hypercholesterolaemia (FH) Studies Collaboration (FHSC) global consortium and registry (established 2015), which broadly addresses burden FH. Eighty-seven National Lead Investigators from 74 countries form this expanding consortium, currently includes pooled data on almost 70,000 participants participating to facilitate FH surveillance. Published first results concluded that diagnosed late, management LDL-cholesterol falls below guideline...